Quanterix Garners New Funding Round

  • Feed Type
  • Date
    1/5/2012
  • Company Name
    Quanterix
  • Mailing Address
    One Kendall Square Building 1400 Cambridge, MA 02139
  • Company Description
    At Quanterix, our principal focus is to improve human health by providing physicians, drug developers, and researchers with the ability to detect and analyze important biomolecules within complex biological samples at the level of single molecules. The company was founded in June 2007 by successful entrepreneurs Dr. David Walt and Dr. Nick Naclerio. Quanterix is the exclusive licensee of a broad intellectual property portfolio from the Walt laboratory at Tufts University.

    Quanterix has utilized the ability to detect single molecules to quantify the concentration of proteins in human serum at levels that are more than a thousand fold lower than the gold standard ELISA assay. This capability is important because, of the thousands of proteins and protein isoforms that are predicted to exist in human blood, only a couple of hundred have been measured, and of those many are below the detection limit of current assays in normal individuals.

  • Website
    http://www.quanterix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    Undisclosed
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The company will use the funding to help expand the development of its technology to detect pathogens.
  • M&A Terms
  • Venture Investor
    In-Q-Tel (IQT)

By posting a comment, you agree to our terms and conditions.